REGENXBIO Announces NAV® Technology Platform Will Support Bespoke Gene Therapy Consortium’s First Rare Disease Clinical Portfolio
Major Players Include Johnson & Johnson, Novartis, Hoffmann-La Roche, Novo Nordisk and Bayer
Fresh2 Files Annual Report on Form 20-F for Fiscal Year 2022
St. Joseph’s Hospital Appoints New Vice President, Chief Medical Officer
Jewett-Cameron announces adoption of Advance Notice Policy
America’s Best Wings: Everything You Need to Know
Beijing Express: Fabrice and Briac stop in the Gers to promote the fight against cancer
Exfoliation, hydration: honey, a nectar with many virtues for the skin
“He’s fine” … Michel Drucker released from hospital after having heart surgery
Vegetable crisps, a healthy alternative?
Eating broccoli against skin allergies
Research in MPS IVA led by REGENXBIO scientists moving into clinic Donation of NAV® Technology licenses will support development of gene therapies for rare diseases ROCKVILLE,...